Company:  OREXIGEN THERAPEUTICS, IN ... (OREX)
Form Type:  8-K
Filing Date:  5/9/2012 
CIK:  0001382911 
Address:  3344 N. TORREY PINES CT.
SUITE 200
 
City, State, Zip:  LA JOLLA, California 92037 
Telephone:  (858) 875-8600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.94  
Change: 
-0.04 (-0.67%)  
Trade Time: 
Dec 26  
Market Cap: 
$731.61M
Description of Business
Orexigen� Therapeutics, Inc. (�Orexigen�, �we�, �our� and �us�) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Our product candidates are NB32 (formerly referred to as Contrave�), which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic�, which has completed Phase II clinical trials. Each of these product candidates is a combination of generic drug components, each of which has already received regulatory approval for other indications and been commercialized in the United States and in a majority of the member countries of the European Union. NB32 is a combination of two well-established drugs, bupropion and naltrexone, each in a sustained release, or SR, formulation. Bupropion is a widely prescribed antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction.
Register for a Free Trial and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02 Results of Operations and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1
    BALANCE SHEET
    INCOME STATEMENT